BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a ...

BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a ...

MOL PLUS has decided to invest in Pyxis Maritime, a Singapore-based developer of electric vessels and operator of electric boat charging stations, as part of efforts to promote the commercialization ...

Pyxis secured S$13 million in the first close of its S$18 million growth funding round, reflecting strong investor confidence in its vessel technology, commercial traction, and regional growth ...

Pyxis Oncology Inc. (NASDAQ: PYXS) on Thursday released preliminary data from its ongoing Phase 1 studies of micvotabart pelidotin (MICVO) for recurrent/metastatic head and neck squamous cell ...

Shares of Pyxis Oncology dropped after the pharmaceutical company said data from its trials on a treatment for a form of head and neck cancer showed a high incidence of adverse effects. The stock fell ...

Pyxis Oncology ( (PYXS)) has provided an announcement. On December 18, 2025, Pyxis Oncology reported positive preliminary Phase 1 data for its first-in-concept antibody-drug conjugate MICVO in ...

Investing.com - Pyxis Oncology Inc. (NASDAQ:PYXS) shares declined after RBC Capital lowered its price target to $5.00 from $8.00 while maintaining an Outperform rating. The adjustment follows Pyxis ...

Investing.com -- Pyxis Oncology Inc (NASDAQ:PYXS) stock tumbled 49.9% in premarket trading Thursday after investors expressed disappointment with preliminary data from the company’s experimental ...

46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in ...

For James Westlake, a recent Naked Wines campaign required a camera able to produce excellent images in a fast, lightweight, handheld setup, and the PYXIS 12K fit the bill. James Westlake is a UK ...